In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...

Christopher Locher, PhD, CEO, Versatope Therapeutics, Inc., tells his us about his version of a universal flu vaccine while ...

The hesitation reflects a difficult balancing act for the administration as it prepares for midterm elections. Kennedy's MAHA ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Foundayo’s approval also makes history as the first new molecular entity (NME) approved under the National Priority Voucher ...

Alistair leads UCB's global research and early development organisation with a mission to bring scientific innovation to patients living with severe diseases. A biophysicist by training and drug ...

Biogen acquires Apellis Pharmaceuticals in a deal that brings two marketed complement therapies into its portfolio, ...

Every aspect of science carries risk. In research, the equation could be expressed as: clear portfolio boundaries + ...

In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy ...

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...

The new multi-month subscription program launched March 31, 2026 offers eligible self-pay patients a fixed monthly price for ...

Eli Lilly agreed to acquire Centessa Pharmaceuticals for approximately $7.8 billion, expanding its neuroscience pipeline. Eli ...